Carfilzomib Multiple Myeloma Data Do New Onyx Parent Proud At ASH '09
This article was originally published in The Pink Sheet Daily
Executive Summary
When all else fails, call on carfilzomib: Phase II data support end-2010 NDA filing for next-generation Velcade.
You may also be interested in...
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
Carfilzomib On Track For End-of-Year Submission After Surprising Top-line Phase II Results
Onyx's next-generation proteasome inhibitor shows a 24% response rate, 7.4 month durable response as a salvage therapy in multiple myeloma.